Navigation Links
Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
Date:3/30/2009

Largest Study on a Test that Identifies Tumors with Uncertain Origins Demonstrates Unmatched Performance

REDWOOD CITY, Calif., March 30 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, announced today that the Journal of Clinical Oncology (JCO) has published the results of the Pathwork(R) Tissue of Origin Test validation study in a paper entitled, "Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin." The results of the 547-specimen study showed that the test has significant potential to reduce diagnostic uncertainty for poorly differentiated, undifferentiated or metastatic tumors. To date, no other tests in this category have undergone as large a clinical validation study or produced such strong results.

"This study, which is the first of many clinical studies being performed, clearly demonstrates the exceptional performance and robust science underlying our test," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "We believe the Tissue of Origin Test can benefit physicians by allowing them to diagnose tumors with uncertain origins with greater confidence because the test provides objective data and the ability to both rule in and rule out tumor types."

To determine the tumor's origin, the Pathwork Tissue of Origin Test uses microarray technology to measure the gene expression pattern, comprising more than 1,500 genes, in a tumor with an uncertain origin and compare it to expression patterns of a panel of 15 known tumor types, representing 90 percent of all solid tumors and 58 morphologies overall. In the multicenter, blinded clinical validation study, which was used as the basis for the test's FDA clearance in July 2008, the test examined 547 frozen tumor specimens from patients diagnosed with one of the tumor types in the panel, all of which were either metastatic, poorly differentiated or undifferentiated. The test demonstrated 88% positive percent agreement (akin to sensitivity) and greater than 99% negative percent agreement (akin to specificity) with available diagnoses. Although the JCO paper only reported results for frozen tissue samples, a separate validation study performed by Pathwork with FFPE (formalin-fixed, paraffin-embedded) specimens showed similar performance. Both the frozen and FFPE versions of the test are commercially available as a service through Pathwork Diagnostics Laboratory.

The paper published in the American Society of Clinical Oncology's journal was authored by Federico Monzon, M.D., Director of Molecular Diagnostics at The Methodist Hospital in Houston, Texas. Dr. Monzon's results showed that the test should become a valuable complement to currently available diagnostic methods for tumors with uncertain origins. The abstract can be read online at http://jco.ascopubs.org/ and the full paper is available for download on www.pathworkdx.com.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Redwood City, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market - the Pathwork(R) Tissue of Origin Test - utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. For more information, call 1.877.808.0006 or visit www.pathworkdx.com.

Copyright (C) 2009 Pathwork Diagnostics, Inc. All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics and the Pathwork Tissue of Origin logos are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.

    CONTACT:
    Jane Woo
    +1-415-608-1515
    media@pathworkdx.com


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Pathwork Diagnostics Collaborates With Guys and St Thomas on Tissue of Origin Test Validation in the UK
4. Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens
5. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
6. USC researcher identifies stem cells in tendons that regenerate tissue in animal model
7. Stem cells derived from adult testes produce wide range of tissue types
8. Stem Cells From Testes Produce Wide Range of Tissue Types
9. Tissue-Growth Gene Tied to Scleroderma
10. Two Million Californians Say Yes! to Organ and Tissue Donation
11. Starion Instruments Launches Next-Generation Tissue Ligating Shears at the American College of Surgeons Clinical Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
(Date:4/29/2016)... ... 29, 2016 , ... Intellitec Solutions will be a sponsor ... at the Broward County Convention Center. The event is a chance for finance ... in public facility management. Intellitec Solutions will highlight their customized accounting solutions designed ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Pro3rd ... X. Utilize Pixel Film Studios’ lower thirds to introduce people, characters, and locations without ... that include boxes, lines, accents, textures and many more design components. Simply select a ...
(Date:4/29/2016)... ... April 29, 2016 , ... The number of chronically and seriously ill individuals ... there is an urgent need for highly skilled care managers and care coordinators. ... approach to train and retain care managers, and enhance their skills. , ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... and providers, recently announced that their founders, Dr. Gemmi and Dr. Middleberg, were ... over 550 orthodontists around the nation. During the seminar, titled “Advancing the ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: SHPG ... will present at the Deutsche Bank 41st Annual Health Care ... May 04, 2016, 10:00 am EDT (15:00 BST). ... and Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/ ... on this same website for approximately 90 days. ...
Breaking Medicine Technology: